Confusion in the monitoring of coagulation function in pregnant and neonate patients with severe disease: A case reports and brief literature review

Medicine (Baltimore). 2023 Nov 17;102(46):e35997. doi: 10.1097/MD.0000000000035997.

Abstract

Rationale: Different populations have their own unique physiological and pathological characteristics. However, in specialized maternal and child hospitals, there is currently a lack of standardized methods for assessing coagulation dysfunction, both domestically and internationally.

Patient concerns: A 19-day-old neonate was transferred to neonatal intensive care unit with cyanosis, nasal bleeding for 6 hours, and a consciousness disorder for 5 hours. A 33-year-old woman presented with hydramnios and a 39 + 3week intrauterine pregnancy. All indicators before delivery were normal, but postpartum hemorrhage occurred after delivery.

Diagnoses: We retrospectively analyzed 1 neonate with pulmonary hemorrhage accompanied by thrombocytopenia and 1 pregnant patient with amniotic fluid embolism.

Interventions: The new coagulation indicators, such as thrombin-antithrombin complex, plasmin-alpha 2 antiplasmin complex, thrombomodulin, and tissue plasminogen activator-plasminogen activator inhibitor-1 complex, have been indicated to be valuable. In neonates, it is necessary to continuously monitor special items combined with specific therapeutic agents, such as tranexamic acid. In cases where postpartum hemorrhage occurs with low fibrinogen levels, it is essential to effectively identify patients with severe amniotic fluid embolism from a high incidence of specimen clotting.

Outcomes: The neonate's oxygen saturation stabilized, and after 5 days of treatment with low molecular weight heparin, thrombin-antithrombin complex and plasmin-alpha 2 antiplasmin complex returned to normal levels. The pregnant began to remove the remaining thrombus, the patient's condition recovered, and she had a good prognosis.

Lessons: For pregnant and neonatal critical illnesses, it is necessary to develop personalized coagulation monitoring programs that provide realistic and reasonable treatment recommendations. Such programs should consider the unique physiological and pathological characteristics of different populations to ensure effective management of critically ill patients.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Consciousness Disorders
  • Embolism, Amniotic Fluid* / drug therapy
  • Female
  • Fibrinolysin
  • Fibrinolysis / physiology
  • Humans
  • Infant, Newborn
  • Postpartum Hemorrhage* / drug therapy
  • Pregnancy
  • Retrospective Studies
  • Tissue Plasminogen Activator / therapeutic use
  • alpha-2-Antiplasmin

Substances

  • alpha-2-Antiplasmin
  • Fibrinolysin
  • Tissue Plasminogen Activator